S&P 500   5,087.03
DOW   39,069.11
QQQ   438.07
Top-Rated AMD nears major breakout level
Americans Now Favor Gold Over Stocks as an Investment Vehicle (Ad)
Roku stock and the mother of all entry opportunities
AI powerhouse NVIDIA will hit $1000 soon
Americans Now Favor Gold Over Stocks as an Investment Vehicle (Ad)
Nvidia, Royal Caribbean rise; Rivian, Etsy fall, Thursday, 2/22/2024
Rivian shares gets discounted; shares can move lower 
The Strategic Gold Play You Haven't Heard About (Ad)
The Trade Desk: 3 reasons to buy before a new all-time high
Wall Street sees a solid year ahead for homebuilders, though mortgage rates remain a wildcard
S&P 500   5,087.03
DOW   39,069.11
QQQ   438.07
Top-Rated AMD nears major breakout level
Americans Now Favor Gold Over Stocks as an Investment Vehicle (Ad)
Roku stock and the mother of all entry opportunities
AI powerhouse NVIDIA will hit $1000 soon
Americans Now Favor Gold Over Stocks as an Investment Vehicle (Ad)
Nvidia, Royal Caribbean rise; Rivian, Etsy fall, Thursday, 2/22/2024
Rivian shares gets discounted; shares can move lower 
The Strategic Gold Play You Haven't Heard About (Ad)
The Trade Desk: 3 reasons to buy before a new all-time high
Wall Street sees a solid year ahead for homebuilders, though mortgage rates remain a wildcard
S&P 500   5,087.03
DOW   39,069.11
QQQ   438.07
Top-Rated AMD nears major breakout level
Americans Now Favor Gold Over Stocks as an Investment Vehicle (Ad)
Roku stock and the mother of all entry opportunities
AI powerhouse NVIDIA will hit $1000 soon
Americans Now Favor Gold Over Stocks as an Investment Vehicle (Ad)
Nvidia, Royal Caribbean rise; Rivian, Etsy fall, Thursday, 2/22/2024
Rivian shares gets discounted; shares can move lower 
The Strategic Gold Play You Haven't Heard About (Ad)
The Trade Desk: 3 reasons to buy before a new all-time high
Wall Street sees a solid year ahead for homebuilders, though mortgage rates remain a wildcard
S&P 500   5,087.03
DOW   39,069.11
QQQ   438.07
Top-Rated AMD nears major breakout level
Americans Now Favor Gold Over Stocks as an Investment Vehicle (Ad)
Roku stock and the mother of all entry opportunities
AI powerhouse NVIDIA will hit $1000 soon
Americans Now Favor Gold Over Stocks as an Investment Vehicle (Ad)
Nvidia, Royal Caribbean rise; Rivian, Etsy fall, Thursday, 2/22/2024
Rivian shares gets discounted; shares can move lower 
The Strategic Gold Play You Haven't Heard About (Ad)
The Trade Desk: 3 reasons to buy before a new all-time high
Wall Street sees a solid year ahead for homebuilders, though mortgage rates remain a wildcard

Surmodics (SRDX) Competitors

$31.87
+0.37 (+1.17%)
(As of 02/22/2024 ET)

SRDX vs. OFIX, ARAY, ANGO, CTSO, ATRC, RCEL, NPCE, CVRX, CERS, and OSUR

Should you be buying Surmodics stock or one of its competitors? The main competitors of Surmodics include Orthofix Medical (OFIX), Accuray (ARAY), AngioDynamics (ANGO), Cytosorbents (CTSO), AtriCure (ATRC), AVITA Medical (RCEL), NeuroPace (NPCE), CVRx (CVRX), Cerus (CERS), and OraSure Technologies (OSUR). These companies are all part of the "surgical & medical instruments" industry.

Surmodics vs.

Orthofix Medical (NASDAQ:OFIX) and Surmodics (NASDAQ:SRDX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their community ranking, risk, valuation, analyst recommendations, institutional ownership, profitability, media sentiment, dividends and earnings.

Surmodics has a net margin of 3.99% compared to Surmodics' net margin of -20.39%. Orthofix Medical's return on equity of 8.06% beat Surmodics' return on equity.

Company Net Margins Return on Equity Return on Assets
Orthofix Medical-20.39% -7.26% -5.15%
Surmodics 3.99%8.06%5.11%

Orthofix Medical has a beta of 1.06, meaning that its stock price is 6% more volatile than the S&P 500. Comparatively, Surmodics has a beta of 1.05, meaning that its stock price is 5% more volatile than the S&P 500.

In the previous week, Orthofix Medical had 2 more articles in the media than Surmodics. MarketBeat recorded 3 mentions for Orthofix Medical and 1 mentions for Surmodics. Surmodics' average media sentiment score of 0.93 beat Orthofix Medical's score of 0.35 indicating that Orthofix Medical is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Orthofix Medical
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Surmodics
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Surmodics has lower revenue, but higher earnings than Orthofix Medical. Orthofix Medical is trading at a lower price-to-earnings ratio than Surmodics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Orthofix Medical$460.71M1.07-$19.75M-$3.90-3.44
Surmodics$132.58M3.42-$1.54M$0.3883.87

Orthofix Medical presently has a consensus price target of $14.00, suggesting a potential upside of 4.24%. Surmodics has a consensus price target of $59.00, suggesting a potential upside of 85.13%. Given Orthofix Medical's stronger consensus rating and higher possible upside, analysts plainly believe Surmodics is more favorable than Orthofix Medical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Orthofix Medical
0 Sell rating(s)
3 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Surmodics
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

Orthofix Medical received 77 more outperform votes than Surmodics when rated by MarketBeat users. However, 66.80% of users gave Surmodics an outperform vote while only 62.06% of users gave Orthofix Medical an outperform vote.

CompanyUnderperformOutperform
Orthofix MedicalOutperform Votes
409
62.06%
Underperform Votes
250
37.94%
SurmodicsOutperform Votes
332
66.80%
Underperform Votes
165
33.20%

89.8% of Orthofix Medical shares are owned by institutional investors. Comparatively, 87.1% of Surmodics shares are owned by institutional investors. 4.7% of Orthofix Medical shares are owned by insiders. Comparatively, 8.9% of Surmodics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Surmodics beats Orthofix Medical on 12 of the 18 factors compared between the two stocks.


Get Surmodics News Delivered to You Automatically

Sign up to receive the latest news and ratings for SRDX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SRDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SRDX vs. The Competition

MetricSurmodicsSurgical & medical instruments IndustryMedical SectorNASDAQ Exchange
Market Cap$448.43M$3.88B$4.98B$7.41B
Dividend YieldN/A2.04%2.91%3.86%
P/E Ratio83.8712.0488.5813.90
Price / Sales3.4225.232,864.3356.15
Price / Cash40.1730.9287.7252.42
Price / Book3.714.054.334.63
Net Income-$1.54M$20.26M$112.32M$207.29M
7 Day Performance1.85%-1.24%0.42%-1.02%
1 Month Performance-8.18%9.91%6.40%3.32%
1 Year Performance33.46%3.30%8.21%3.73%

Surmodics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
OFIX
Orthofix Medical
0.851 of 5 stars
$13.76
-0.2%
$14.00
+1.7%
-35.3%$505.82M$460.71M-3.531,092Positive News
ARAY
Accuray
4.253 of 5 stars
$2.73
-1.8%
$8.25
+202.2%
-11.5%$270.73M$447.61M-18.201,024
ANGO
AngioDynamics
4.0478 of 5 stars
$6.07
-1.9%
$15.00
+147.1%
-53.2%$246.70M$329.54M-17.34815
CTSO
Cytosorbents
1.8559 of 5 stars
$1.02
+1.0%
$2.50
+145.1%
-70.3%$45.33M$34.69M-1.92198News Coverage
ATRC
AtriCure
2.0743 of 5 stars
$33.01
+0.9%
$57.88
+75.3%
-20.0%$1.56B$399.24M-50.021,050
RCEL
AVITA Medical
2.7744 of 5 stars
$17.58
+0.6%
$26.80
+52.4%
+88.0%$449.17M$34.42M-13.22126News Coverage
NPCE
NeuroPace
2.3056 of 5 stars
$17.50
+6.3%
$12.00
-31.4%
+222.3%$459.90M$45.52M-11.67169Analyst Report
News Coverage
CVRX
CVRx
1.8631 of 5 stars
$22.24
-2.4%
$33.67
+51.4%
+135.8%$465.48M$39.29M-11.23200
CERS
Cerus
3.2181 of 5 stars
$2.31
-2.1%
$3.00
+29.9%
-22.1%$418.57M$162.05M-8.25665Upcoming Earnings
Gap Down
OSUR
OraSure Technologies
2.8472 of 5 stars
$6.82
+1.0%
$6.33
-7.1%
+10.5%$501.13M$387.48M10.33840Upcoming Earnings

Related Companies and Tools

This page (NASDAQ:SRDX) was last updated on 2/23/2024 by MarketBeat.com Staff